Side-by-side · Research reference
PTD-DBMvsTesofensine
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED10/40 cited
BPhase 3AUTO-DRAFTED10/40 cited
PTD-DBM
Wnt Pathway Activator · Fusion Peptide
Topical / SQ · Study-dependent
Tesofensine
SNDRI · Phase 3 obesity candidate
Oral · Once daily morning
01Mechanism of Action
Parameter
PTD-DBM
Tesofensine
Primary target
CXXC5–Dishevelled protein-protein interaction
Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008
Pathway
Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008
Downstream effect
Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation
Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008
Feedback intact?
Not applicable — pathway derepression rather than receptor agonism
—
Origin
Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5
Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008
Antibody development
—
—
02Dosage Protocols
Parameter
PTD-DBM
Tesofensine
Wound healing protocol
Hydrogel patch delivery (concentration not disclosed)
Pyrogallol-HA patch, murine model.
—
Hair regeneration protocol
Topical application (exact dose not disclosed)
Wound-induced hair neogenesis model, mice.
—
Co-administration
Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023
Combined treatment maximized scar reduction.
—
Human translation
No published human studies
—
Frequency
—
Once daily, morning
Lower / starter dose
—
0.125 mg / day
Duration
—
24 weeks per studied cycle
Form
—
Oral capsule
Timing
—
Morning to avoid sleep disruption
Half-life
—
~9 days (very long)
04Side Effects & Safety
Parameter
PTD-DBM
Tesofensine
Reported adverse events
None reported in animal studies
—
Wnt pathway activation risks
Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis
—
Long-term safety
Unknown — no chronic dosing or human data
—
Delivery vehicle effects
HA-PG hydrogel well-tolerated in mice; human translation pending
—
Insomnia
—
Dose-related; mitigate with morning timing
Dry mouth
—
Common
Nausea
—
Common
Mood changes
—
Anxiety / agitation possible
Cardiovascular events
—
Phase 3 trial monitoring; not yet FDA-cleared
Pregnancy / OB
—
Contraindicated
Absolute Contraindications
PTD-DBM
- ·Active malignancy (Wnt pathway involvement in tumorigenesis)
- ·Pregnancy / lactation (no safety data)
Tesofensine
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease
- ·Concurrent MAOI use
Relative Contraindications
PTD-DBM
- ·History of Wnt-driven tumors
- ·Skin lesions with uncertain malignant potential
Tesofensine
- ·Hypertension
- ·Anxiety disorder
- ·Insomnia
05Administration Protocol
Parameter
PTD-DBM
Tesofensine
1. Wound Healing Protocol (Animal Model)
Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023
Oral capsule (investigational; not commercial).
2. Hair Regeneration Protocol (Animal Model)
Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023
Swallow whole with water, morning only.
3. Combination Therapy
PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023
Morning to mitigate insomnia. Do not dose evening.
4. Storage & Handling
Not disclosed in available literature. Peptide stability and storage conditions not published.
Room temp ≤25 °C, dry place.
5. Caveat
—
Monitor BP + HR + mood. Avoid stimulants + MAOIs.